References
- Walker JJ. Pre-eclampsia. Lancet 2000;356:1260–5
- Valenzuela FJ, Pérez-Sepúlveda A, Torres MJ, et al. Pathogenesis of preeclampsia: the genetic component. J Pregnancy 2012;2012:632732
- Barakonyi A, Miko E, Szereday L, et al. Cell death mechanisms and potentially cytotoxic natural immune cells in Human pregnancies complicated by preeclampsia. Reprod Sci 2014;21:155–66
- Taylor RN, de Groot CJ, Cho YK, Lim KH. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:17–31
- Chedraui P, Solis EJ, Bocci G, et al. Feto-placental nitric oxide, asymmetric dimethylarginine and vascular endothelial growth factor (VEGF) levels and VEGF gene polymorphisms in severe preeclampsia. J Matern Fetal Neonatal Med 2013;26:226–32
- El-Sherbiny WS, Nasr AS, Soliman A. Endothelial nitric oxide synthase (eNOS) (Glu298Asp) and urotensin II (UTS2 S89N) gene polymorphisms in preeclampsia: prediction and correlation with severity in Egyptian females. Hypertens Pregnancy 2013;32:292–303
- Song GG, Kim JH, Kim YH, et al. Associations between vascular endothelial growth factor gene polymorphisms and pre-eclampsia susceptibility: a meta-analysis. Hum Immunol 2013;74:1206–13
- Barbosa PR, Stabler SP, Machado AL, et al. Association between decreased vitamin levels and MTHFR, MTR and MTRR gene polymorphisms as determinants for elevated total homocysteine concentrations in pregnant women. Eur J Clin Nutr 2008;62:1010–21
- Klai S, Fekih-Mrissa N, El Housaini S, et al. Association of MTHFR A1298C polymorphism (but not of MTHFR C677T) with elevated homocysteine levels and placental vasculopathies. Blood Coagul Fibrinolysis 2011;22:374–8
- Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–13
- Van der Put NM, Gabreels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044–51
- Chedraui P, Salazar-Pousada D, Villao A, et al. Polymorphisms of the methylenetetrahydrofolate reductase gene (C677T and A1298C) in nulliparous women complicated with preeclampsia. Gynecol Endocrinol 2014;30:392–6
- Canto P, Canto-Cetina T, Juárez-Velázquez R, et al. Methylenetetrahydrofolate reductase C677T and glutathione S-transferase P1 A313G are associated with a reduced risk of preeclampsia in Maya-Mestizo women. Hypertens Res 2008;31:1015–19
- American College of Obstetricians and Gynecologists. Hypertension in pregnancy. ACOG, 2013. Available from: http://www.acog.org/Resources_And_Publications/Task_Force_and_Work_Group_Reports/Hypertension_in_Pregnancy [last accessed December 2014]
- Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30:S32–7
- Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008;51:970–5
- Lachmeijer AM1, Dekker GA, Pals G, et al. Searching for preeclampsia genes: the current position. Eur J Obstet Gynecol Reprod Biol 2002;105:94–113
- Chen CW, Jaffe IZ, Karumanchi SA. Pre–eclampsia and cardiovascular disease. Cardiovasc Res 2014;101:579–86
- Hogg BB, Tamura T, Johnston KE, et al. Second-trimester plasma homocysteine levels and pregnancy-induced hypertension, preeclampsia, and intrauterine growth restriction. Am J Obstet Gynecol 2000;183:805–9
- Guilliams TG. Homocysteine – a risk factor for vascular diseases. J Am Neutraceut Assoc 2004;7:11–16
- Thomas P, Fenech M. Methylenetetrahydrofolate reductase, common polymorphisms, and relation to disease. Vitam Horm 2008;79:375–92
- Mislanova C, Martsenyuk O, Huppertz B, Obolenskaya M. Placental markers of folate-related metabolism in preeclampsia. Reproduction 2011;142:467–76
- Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005;366:1797–803